Non-profit Pennsylvania Network Is Expanding
Use of Masimo Patient SafetyNet™, Root® with Radius-7® and Vital
Signs Check to Almost 500 Beds Across 10 Hospitals
St. Luke’s University Health Network (St. Luke’s) and
Masimo (NASDAQ: MASI) announced today that St. Luke’s, a
regional network of 10 hospitals and 320 affiliated sites providing
service to 10 counties in eastern Pennsylvania, is expanding their
use of a variety of Masimo technologies following impressive
outcome results at a pilot site.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190319005899/en/
Four years ago, seeking to improve patient safety and reduce
morbidity and mortality in their hospitals, St. Luke’s formed a
multidisciplinary taskforce – comprised of anesthesiologists,
nurses, respiratory specialists, hospital leaders, and others –
charged with implementing changes and tracking outcomes in a pilot
location, a 34-bed orthopedic trauma ward at their hospital in
Bethlehem. As part of that program, which also involved changes in
clinical practice and alarm management, St. Luke’s installed Masimo
Patient SafetyNet™, a supplemental remote monitoring and clinician
notification system, in the pilot ward. Patients were monitored at
the bedside using the Masimo Root® patient monitoring and
connectivity hub in conjunction with Masimo Radius-7® tetherless,
wearable Pulse CO-Oximeters® that continuously monitor patients’
oxygen saturation and pulse rate using Masimo SET® Measure-through
Motion and Low Perfusion™ pulse oximetry. Through Patient
SafetyNet, these and other parameters can be continuously remotely
monitored from central view stations and even smartphones, with the
ability to alert clinicians from afar to possible deterioration in
patient condition. In 2016, a year after implementation of the
program, clinicians achieved impressive outcome and financial
results compared to 2015 performance, including a 62% reduction in
mortality, a 36% reduction in naloxone administration, a 23%
reduction in the utilization of telemetry, a 26% reduction in
critical care transfers, and an estimated savings of $900,000 in
cost avoidance.
“Because of the unpredictability of which patients will
deteriorate, continuous and in-depth monitoring provides a valuable
level of data that can be acted upon quickly to save lives,” said
Aldo Carmona, MD, Chairman of the Department of Anesthesia and
Critical Care and SVP of Clinical Integration, who leads the
initiative. “Constant monitoring of changes in patient conditions
will alert doctors and nurses when gradual deterioration is sensed,
enabling a quicker therapeutic response and avoiding emergent
situations.”
Following the successful pilot program, St. Luke’s expanded use
of Patient SafetyNet to an additional 48 beds across two additional
units on their Bethlehem campus. Now, three years later, the
network is again expanding use of Patient SafetyNet and other
Masimo solutions to almost 500 beds in total, so that all eight
existing hospitals will have the technology – and in two hospitals
slated to open this year, only Masimo continuous monitoring
technologies will be used outside the ICU. Monitoring data is now
automatically transferred from bedside devices and Patient
SafetyNet to St. Luke’s Epic electronic medical record (EMR)
system, helping improve productivity and reducing the likelihood of
transcription errors.1 Vital Signs Check, an application for Root
designed to streamline vital signs measurement workflows and
optimize patient data management, is also being implemented. “With
the higher acuity levels of many hospitalized patients, taking
vital signs over four or eight hours is no longer effective in many
cases, and developing conditions are missed until they become
critical threats sometimes resulting in poor outcomes,” Dr. Carmona
said.
Speaking of the ongoing expansion and enhancement of their
continuous monitoring program, Dr. Carmona commented, “This Patient
SafetyNet initiative will be the most important patient safety
project I will work on in my whole career.”
St. Luke’s sought inspiration from another institution’s
successful implementation of continuous monitoring using Masimo
SET® and Patient SafetyNet: Dartmouth-Hitchcock Medical Center in
New Hampshire, where researchers found that continuous monitoring
of adult post-surgical patients using Masimo SET® pulse oximetry on
Masimo bedside devices, in conjunction with Masimo Patient
SafetyNet, resulted in a 65% reduction in rapid response team
activations and a 48% reduction in transfers back to the ICU.2 Over
five years, Dartmouth-Hitchcock achieved their goal of zero
preventable deaths or brain damage due to opioids,3 and over ten
years, they maintained a 50% reduction in unplanned transfers and a
60% reduction in rescue events, despite increases in patient acuity
and occupancy.4 With the monitoring of additional physiological
parameters and integration into EMRs, St. Luke’s initiative is set
to provide even more continuous supplemental monitoring coverage
than at Dartmouth-Hitchcock.
Joe Kiani, Founder and CEO of Masimo, said, “We are honored to
partner with St. Luke’s as they continue to expand their patient
safety and monitoring initiatives. Our mission – to improve patient
outcomes and reduce the cost of care – aligns well with their
values. Their ongoing commitment to saving lives through our proven
SET® and Patient SafetyNet technology is a model we hope more and
more institutions will see the benefits of implementing.”
@MasimoInnovates | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative
noninvasive monitoring technologies. Our mission is to improve
patient outcomes and reduce the cost of care. In 1995, the company
debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse
oximetry, which has been shown over 100 independent and objective
studies to outperform other pulse oximetry technologies.5 Masimo
SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,6 improve CCHD screening in
newborns,7 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
activations and costs.2-4 Masimo SET® is estimated to be used on
more than 100 million patients in leading hospitals and other
healthcare settings around the world,8 and is the primary pulse
oximetry at 9 of the top 10 hospitals listed in the 2018-19 U.S.
News and World Report Best Hospitals Honor Roll.9 In 2005, Masimo
introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total
hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®),
and more recently, Oxygen Reserve Index (ORi™), in addition to
SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and connectivity
platform with the Masimo Open Connect® (MOC-9®) interface, enabling
other companies to augment Root with new features and measurement
capabilities. Masimo is also taking an active leadership role in
mHealth with products such as the Radius-7® wearable patient
monitor, iSpO2® pulse oximeter for smartphones, and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and
its products may be found at www.masimo.com. Published clinical
studies on Masimo products can be found at
http://www.masimo.com/evidence/featured-studies/feature/.
ORi has not received FDA 510(k) clearance and is not available
for sale in the United States. The use of the trademark Patient
SafetyNet is under license from University HealthSystem
Consortium.
References
1. The Value of Medical Device
Interoperability. West Health Institute. 2013. 2. Taenzer AH et al.
Impact of pulse oximetry surveillance on rescue events and
intensive care unit transfers: a before-and-after concurrence
study. Anesthesiology. 2010:112(2):282-287. 3. Taenzer A et al.
Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012. 4.
McGrath SP et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302. 5.
Published clinical studies on pulse
oximetry and the benefits of Masimo SET® can be found on our
website at http://www.masimo.com. Comparative studies include
independent and objective studies which are comprised of abstracts
presented at scientific meetings and peer-reviewed journal
articles
6. Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92. 7. de-Wahl
Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338. 8. Estimate: Masimo data on file. 9.
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
About St. Luke’s
Founded in 1872, St. Luke’s University Health Network (SLUHN) is
a fully integrated, regional, non-profit network of more than
15,000 employees providing services at 10 hospitals and over 320
outpatient sites. With annual net revenue greater than $2 billion,
the Network’s service area includes 10 counties: Lehigh,
Northampton, Berks, Bucks, Carbon, Montgomery, Monroe and
Schuylkill counties in Pennsylvania and Warren and Hunterdon
counties in New Jersey. Dedicated to advancing medical education,
St. Luke’s is the preeminent teaching hospital in central-eastern
Pennsylvania. In partnership with Temple University, St. Luke’s
created the Lehigh Valley’s first and only regional medical school
campus. It also operates the nation’s longest continuously
operating School of Nursing, established in 1884, and 28 fully
accredited graduate medical educational programs with 226 residents
and fellows. St. Luke’s is the only Lehigh Valley-based health care
system with Medicare’s five- and four-star ratings (the highest)
for quality, efficiency and patient satisfaction. St. Luke’s is
both a Leapfrog Group and Healthgrades Top Hospital. In 2019, three
of IBM Watson Health’s 100 Top Hospitals were St. Luke’s hospitals.
St. Luke’s University Hospital has earned the 100 Top Major
Teaching Hospital designation from IBM Watson Health seven times
total and five years in a row. St. Luke’s has also been cited by
IBM Watson Health as a 50 Top Cardiovascular Program. Utilizing the
Epic electronic medical record (EMR) system for both inpatient and
outpatient services, the Network is a multi-year recipient of the
Most Wired award recognizing the breadth of the SLUHN’s information
technology applications such as telehealth, online scheduling and
online pricing information. St. Luke’s is also recognized as one of
the state’s lowest cost providers.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo Patient SafetyNet™,
SET®, Root®, and Radius-7®. These forward-looking statements are
based on current expectations about future events affecting us and
are subject to risks and uncertainties, all of which are difficult
to predict and many of which are beyond our control and could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo Patient SafetyNet, SET®, Root, and
Radius-7, contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique
advantages; as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained
for free at the SEC's website at www.sec.gov. Although we believe
that the expectations reflected in our forward-looking statements
are reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190319005899/en/
Media Contacts:MasimoEvan
Lamb949-396-3376elamb@masimo.com
St. Luke’sSam Kennedy, Corporate Communications
Director484-526-4134Samuel.kennedy@sluhn.org
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024